JP2013501030A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013501030A5 JP2013501030A5 JP2012523341A JP2012523341A JP2013501030A5 JP 2013501030 A5 JP2013501030 A5 JP 2013501030A5 JP 2012523341 A JP2012523341 A JP 2012523341A JP 2012523341 A JP2012523341 A JP 2012523341A JP 2013501030 A5 JP2013501030 A5 JP 2013501030A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- atoms
- side chain
- acid residue
- compound according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000000539 amino acid group Chemical group 0.000 claims 25
- 150000001875 compounds Chemical class 0.000 claims 22
- 125000004432 carbon atom Chemical group C* 0.000 claims 19
- 108090000765 processed proteins & peptides Proteins 0.000 claims 12
- 229920006395 saturated elastomer Polymers 0.000 claims 7
- 150000001413 amino acids Chemical group 0.000 claims 6
- 125000004122 cyclic group Chemical group 0.000 claims 6
- 125000001931 aliphatic group Chemical group 0.000 claims 5
- -1 cyclohexenyl glycine Chemical compound 0.000 claims 5
- JJMDCOVWQOJGCB-UHFFFAOYSA-N 5-aminopentanoic acid Chemical compound [NH3+]CCCCC([O-])=O JJMDCOVWQOJGCB-UHFFFAOYSA-N 0.000 claims 4
- MBZXSJWDBIIBLL-GDVGLLTNSA-N Homoisoleucine Chemical compound CCC(C)C[C@H](N)C(O)=O MBZXSJWDBIIBLL-GDVGLLTNSA-N 0.000 claims 4
- 239000003112 inhibitor Substances 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- OGNSCSPNOLGXSM-UHFFFAOYSA-N 2,4-diaminobutyric acid Chemical compound NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 claims 3
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 claims 3
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 3
- 239000004472 Lysine Substances 0.000 claims 3
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 claims 3
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 claims 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims 3
- 229940024606 amino acid Drugs 0.000 claims 3
- 235000001014 amino acid Nutrition 0.000 claims 3
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 3
- 229960003104 ornithine Drugs 0.000 claims 3
- LOVUSASSMLUWRR-REOHCLBHSA-N (2s)-2-hydrazinylpropanoic acid Chemical compound NN[C@@H](C)C(O)=O LOVUSASSMLUWRR-REOHCLBHSA-N 0.000 claims 2
- GDJDPCVXZBFMKY-UHFFFAOYSA-N 2-(cyclopenten-1-ylamino)acetic acid Chemical compound OC(=O)CNC1=CCCC1 GDJDPCVXZBFMKY-UHFFFAOYSA-N 0.000 claims 2
- LRHRHAWNXCGABU-UHFFFAOYSA-N 2-(cyclopentylazaniumyl)acetate Chemical compound OC(=O)CNC1CCCC1 LRHRHAWNXCGABU-UHFFFAOYSA-N 0.000 claims 2
- JINGUCXQUOKWKH-UHFFFAOYSA-N 2-aminodecanoic acid Chemical compound CCCCCCCCC(N)C(O)=O JINGUCXQUOKWKH-UHFFFAOYSA-N 0.000 claims 2
- QUBNFZFTFXTLKH-UHFFFAOYSA-N 2-aminododecanoic acid Chemical compound CCCCCCCCCCC(N)C(O)=O QUBNFZFTFXTLKH-UHFFFAOYSA-N 0.000 claims 2
- AKVBCGQVQXPRLD-UHFFFAOYSA-N 2-aminooctanoic acid Chemical compound CCCCCCC(N)C(O)=O AKVBCGQVQXPRLD-UHFFFAOYSA-N 0.000 claims 2
- SNDPXSYFESPGGJ-UHFFFAOYSA-N 2-aminopentanoic acid Chemical compound CCCC(N)C(O)=O SNDPXSYFESPGGJ-UHFFFAOYSA-N 0.000 claims 2
- FMUMEWVNYMUECA-UHFFFAOYSA-N 2-azaniumyl-5-methylhexanoate Chemical compound CC(C)CCC(N)C(O)=O FMUMEWVNYMUECA-UHFFFAOYSA-N 0.000 claims 2
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 claims 2
- 241000701022 Cytomegalovirus Species 0.000 claims 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 2
- 239000004471 Glycine Substances 0.000 claims 2
- 208000009889 Herpes Simplex Diseases 0.000 claims 2
- 241000725303 Human immunodeficiency virus Species 0.000 claims 2
- 241000701806 Human papillomavirus Species 0.000 claims 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims 2
- 229930182844 L-isoleucine Natural products 0.000 claims 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims 2
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 claims 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims 2
- 230000001775 anti-pathogenic effect Effects 0.000 claims 2
- 239000003443 antiviral agent Substances 0.000 claims 2
- 235000003704 aspartic acid Nutrition 0.000 claims 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims 2
- 125000001047 cyclobutenyl group Chemical group C1(=CCC1)* 0.000 claims 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 2
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 claims 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 2
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 claims 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
- 235000013922 glutamic acid Nutrition 0.000 claims 2
- 239000004220 glutamic acid Substances 0.000 claims 2
- 208000015181 infectious disease Diseases 0.000 claims 2
- 229960000310 isoleucine Drugs 0.000 claims 2
- 150000002632 lipids Chemical class 0.000 claims 2
- 235000018977 lysine Nutrition 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 2
- 125000006413 ring segment Chemical group 0.000 claims 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 2
- NPDBDJFLKKQMCM-UHFFFAOYSA-N tert-butylglycine Chemical compound CC(C)(C)C(N)C(O)=O NPDBDJFLKKQMCM-UHFFFAOYSA-N 0.000 claims 2
- 238000011282 treatment Methods 0.000 claims 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims 1
- 125000000981 3-amino-3-oxopropyl group Chemical group [H]C([*])([H])C([H])([H])C(=O)N([H])[H] 0.000 claims 1
- 125000003974 3-carbamimidamidopropyl group Chemical group C(N)(=N)NCCC* 0.000 claims 1
- 125000004042 4-aminobutyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])N([H])[H] 0.000 claims 1
- UQXNEWQGGVUVQA-UHFFFAOYSA-N 8-aminooctanoic acid Chemical compound NCCCCCCCC(O)=O UQXNEWQGGVUVQA-UHFFFAOYSA-N 0.000 claims 1
- 208000035143 Bacterial infection Diseases 0.000 claims 1
- KXDHJXZQYSOELW-UHFFFAOYSA-N Carbamic acid Chemical compound NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 claims 1
- 241000606153 Chlamydia trachomatis Species 0.000 claims 1
- 229920000858 Cyclodextrin Polymers 0.000 claims 1
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 claims 1
- 241000450599 DNA viruses Species 0.000 claims 1
- 229920002307 Dextran Polymers 0.000 claims 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 claims 1
- QNAYBMKLOCPYGJ-UWTATZPHSA-N L-Alanine Natural products C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 claims 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims 1
- 229930064664 L-arginine Natural products 0.000 claims 1
- 235000014852 L-arginine Nutrition 0.000 claims 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims 1
- 229930182816 L-glutamine Natural products 0.000 claims 1
- 239000004395 L-leucine Substances 0.000 claims 1
- 235000019454 L-leucine Nutrition 0.000 claims 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims 1
- 241000588652 Neisseria gonorrhoeae Species 0.000 claims 1
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 125000002252 acyl group Chemical group 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 239000000443 aerosol Substances 0.000 claims 1
- 229960003767 alanine Drugs 0.000 claims 1
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 150000001408 amides Chemical class 0.000 claims 1
- 230000000840 anti-viral effect Effects 0.000 claims 1
- 239000004599 antimicrobial Substances 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 208000022362 bacterial infectious disease Diseases 0.000 claims 1
- 230000001588 bifunctional effect Effects 0.000 claims 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 claims 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 229940038705 chlamydia trachomatis Drugs 0.000 claims 1
- MQANMCFSNPBYCQ-UHFFFAOYSA-N decan-2-amine Chemical compound CCCCCCCCC(C)N MQANMCFSNPBYCQ-UHFFFAOYSA-N 0.000 claims 1
- 239000000412 dendrimer Substances 0.000 claims 1
- 229920000736 dendritic polymer Polymers 0.000 claims 1
- 150000004985 diamines Chemical class 0.000 claims 1
- 125000005442 diisocyanate group Chemical group 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 241001493065 dsRNA viruses Species 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 239000000499 gel Substances 0.000 claims 1
- 150000002357 guanidines Chemical group 0.000 claims 1
- 125000001183 hydrocarbyl group Chemical group 0.000 claims 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims 1
- 229960001438 immunostimulant agent Drugs 0.000 claims 1
- 239000003022 immunostimulating agent Substances 0.000 claims 1
- 230000003308 immunostimulating effect Effects 0.000 claims 1
- 229940124524 integrase inhibitor Drugs 0.000 claims 1
- 239000002850 integrase inhibitor Substances 0.000 claims 1
- 229960003136 leucine Drugs 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 239000011159 matrix material Substances 0.000 claims 1
- 238000012986 modification Methods 0.000 claims 1
- 230000004048 modification Effects 0.000 claims 1
- 239000002324 mouth wash Substances 0.000 claims 1
- 229940051866 mouthwash Drugs 0.000 claims 1
- 239000002674 ointment Substances 0.000 claims 1
- 230000001717 pathogenic effect Effects 0.000 claims 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims 1
- 229920000580 poly(melamine) Polymers 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims 1
- 230000028327 secretion Effects 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- WPLOVIFNBMNBPD-ATHMIXSHSA-N subtilin Chemical compound CC1SCC(NC2=O)C(=O)NC(CC(N)=O)C(=O)NC(C(=O)NC(CCCCN)C(=O)NC(C(C)CC)C(=O)NC(=C)C(=O)NC(CCCCN)C(O)=O)CSC(C)C2NC(=O)C(CC(C)C)NC(=O)C1NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C1NC(=O)C(=C/C)/NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C2NC(=O)CNC(=O)C3CCCN3C(=O)C(NC(=O)C3NC(=O)C(CC(C)C)NC(=O)C(=C)NC(=O)C(CCC(O)=O)NC(=O)C(NC(=O)C(CCCCN)NC(=O)C(N)CC=4C5=CC=CC=C5NC=4)CSC3)C(C)SC2)C(C)C)C(C)SC1)CC1=CC=CC=C1 WPLOVIFNBMNBPD-ATHMIXSHSA-N 0.000 claims 1
- 239000012049 topical pharmaceutical composition Substances 0.000 claims 1
- 229960004295 valine Drugs 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ITMI2009A001425A IT1395137B1 (it) | 2009-08-05 | 2009-08-05 | Nuovi peptidi antipatogeni |
| ITMI2009A001425 | 2009-08-05 | ||
| PCT/EP2010/061424 WO2011015628A1 (en) | 2009-08-05 | 2010-08-05 | Novel antipathogenic peptides |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013501030A JP2013501030A (ja) | 2013-01-10 |
| JP2013501030A5 true JP2013501030A5 (OSRAM) | 2013-09-12 |
Family
ID=42046263
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012523341A Pending JP2013501030A (ja) | 2009-08-05 | 2010-08-05 | 新規抗病原性ペプチド |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US8877738B2 (OSRAM) |
| EP (1) | EP2462155B1 (OSRAM) |
| JP (1) | JP2013501030A (OSRAM) |
| CN (1) | CN102574893A (OSRAM) |
| AU (1) | AU2010280682A1 (OSRAM) |
| CA (1) | CA2768748A1 (OSRAM) |
| IT (1) | IT1395137B1 (OSRAM) |
| WO (1) | WO2011015628A1 (OSRAM) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2538335T3 (es) | 2013-05-14 | 2015-06-19 | Najöpharm Gmbh I.G. | Combinación de ácido poliacrílico y 2-amino-2-metilpropanol para uso en el tratamiento de infecciones por herpes |
| US10702572B2 (en) * | 2015-07-28 | 2020-07-07 | Carnegie Mellon University | Methods and compounds to suppress viral genome release and packaging |
| RU2655763C2 (ru) * | 2016-10-24 | 2018-05-29 | Общество С Ограниченной Ответственностью "Айвикс" | Фармацевтическая композиция и способ лечения женских сексуальных дисфункций |
| US11174288B2 (en) | 2016-12-06 | 2021-11-16 | Northeastern University | Heparin-binding cationic peptide self-assembling peptide amphiphiles useful against drug-resistant bacteria |
| CN120349386B (zh) * | 2025-04-29 | 2025-11-28 | 中国农业科学院兰州兽医研究所(中国动物卫生与流行病学中心兰州分中心) | 人工合成多肽p2及其在抗疱疹病毒感染中的应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU6005698A (en) * | 1997-02-20 | 1998-09-09 | Yeda Research And Development Co. Ltd. | Antipathogenic synthetic peptides and compositions comprising them |
| US6660843B1 (en) * | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
| US20090087878A9 (en) * | 1999-05-06 | 2009-04-02 | La Rosa Thomas J | Nucleic acid molecules associated with plants |
| AUPR412801A0 (en) | 2001-03-30 | 2001-05-03 | Starpharma Limited | Agent for the prevention and treatment of sexually transmitted disease s - I |
| WO2003084477A2 (en) * | 2002-03-29 | 2003-10-16 | Centocor, Inc. | Mammalian cdr mimetibodies, compositions, methods and uses |
| JP2007508011A (ja) * | 2003-09-30 | 2007-04-05 | セントカー・インコーポレーテツド | ヒトヒンジコアミメティボディ、組成物、方法および用途 |
| US20060127404A1 (en) * | 2003-09-30 | 2006-06-15 | Chichi Huang | Hinge core mimetibodies, compositions, methods and uses |
| EP1773400A2 (en) * | 2004-07-08 | 2007-04-18 | Amgen Inc. | Therapeutic peptides |
| EP1778271B1 (en) | 2004-08-18 | 2008-10-22 | IPF Pharmaceuticals GmbH | Peptides for the treatment of herpes virus infections |
| EP2061886B1 (en) * | 2006-08-21 | 2014-05-07 | The University Of British Columbia | Small cationic immunomodulatory peptides |
| WO2009024445A1 (en) * | 2007-08-22 | 2009-02-26 | Ribovax Biotechnologies Sa | Antibodies against human cytomegalovirus (hcmv) |
-
2009
- 2009-08-05 IT ITMI2009A001425A patent/IT1395137B1/it active
-
2010
- 2010-08-05 WO PCT/EP2010/061424 patent/WO2011015628A1/en not_active Ceased
- 2010-08-05 EP EP10739940.4A patent/EP2462155B1/en not_active Not-in-force
- 2010-08-05 US US13/387,154 patent/US8877738B2/en not_active Expired - Fee Related
- 2010-08-05 AU AU2010280682A patent/AU2010280682A1/en not_active Abandoned
- 2010-08-05 JP JP2012523341A patent/JP2013501030A/ja active Pending
- 2010-08-05 CN CN2010800283316A patent/CN102574893A/zh active Pending
- 2010-08-05 CA CA2768748A patent/CA2768748A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013501030A5 (OSRAM) | ||
| NZ595037A (en) | Inhibition of biofilm organisms by combination of cysteamine and repetitive peptides | |
| RU2008126305A (ru) | Новый пептид | |
| JP2014509838A5 (OSRAM) | ||
| JP2013500990A5 (OSRAM) | ||
| UA103882C2 (uk) | Композиція пухлино-асоційованих пептидів та відповідна протиракова вакцина | |
| JP2014515762A5 (OSRAM) | ||
| JP2014514365A5 (OSRAM) | ||
| JP2015513533A5 (OSRAM) | ||
| MY163100A (en) | Short antimicrobial lipopeptides | |
| JP2017533218A5 (OSRAM) | ||
| EP3000481A3 (en) | Peptide-mediated non-covalent delivery of active agent agents across the blood brain barrier | |
| JP2017501990A5 (OSRAM) | ||
| JP2015528443A5 (OSRAM) | ||
| JP2013509389A5 (OSRAM) | ||
| RU2013102991A (ru) | Связанные с дипептидом лекарственные средства | |
| RU2013101051A (ru) | Новый пептид и его применение | |
| RU2015139688A (ru) | Композиция для косметического использования, пригодная для оказания пигментирующего воздействия на волосы | |
| AU2017228333C1 (en) | Stapled intracellular-targeting antimicrobial peptides to treat infection | |
| HRP20140466T1 (hr) | Antimikrobni spojevi | |
| JP2008514586A5 (OSRAM) | ||
| NZ593524A (en) | A nonapeptide with anti-tumour activity | |
| JP2010536714A5 (OSRAM) | ||
| NZ756128A (en) | Novel peptides and analogs for use in the treatment of oral mucositis | |
| JP2015519359A5 (OSRAM) |